Show simple item record

dc.contributor.authorBüyüktimkin, Barlas
dc.contributor.authorWang, Qun
dc.contributor.authorKiptoo, Paul
dc.contributor.authorStewart, John M.
dc.contributor.authorBerkland, Cory J.
dc.contributor.authorSiahaan, Teruna J.
dc.date.accessioned2017-05-10T18:53:05Z
dc.date.available2017-05-10T18:53:05Z
dc.date.issued2012-04-02
dc.identifier.citationBüyüktimkin, B., Wang, Q., Kiptoo, P., Stewart, J. M., Berkland, C., & Siahaan, T. J. (2012). Vaccine-like Controlled-Release Delivery of an Immunomodulating Peptide to Treat Experimental Autoimmune Encephalomyelitis. Molecular Pharmaceutics, 9(4), 979–985. http://doi.org/10.1021/mp200614qen_US
dc.identifier.urihttp://hdl.handle.net/1808/24084
dc.description.abstractThe objective of this work is to use colloidal gel from alginate-chitosan-PLGA complex to deliver Ac-PLP-BPI-NH2-2 peptide in a controlled-release manner as a vaccine-like therapeutic to suppress experimental autoimmune encephalomyelitis (EAE) in the mouse model. Oppositely charged PLGA nanoparticles were prepared by a solvent diffusion method. The carboxyl group of the alginate and the amine group of the chitosan coated the nanoparticles with negative and positive charges, respectively. The peptide (Ac-PLP-BPI-NH2-2), designed to bind to MHC-II and ICAM-1 simultaneously, was formulated into the colloidal gel by physical mixture. Vaccine-like administration of the peptide-loaded colloidal gel (Ac-PLP-BPI-NH2-2-NP) was achieved by subcutaneous (s.c.) injection to EAE mice. Disease severity was measured using clinical scoring and percent change in body weight. Cytokine production was determined using the splenocytes from Ac-PLP-BPI-NH2-2-NP-treated mice and compared to that of controls. Ac-PLP-BPI-NH2-2-NP suppressed and delayed the onset of EAE as well as Ac-PLP-BPI-NH2-2 when delivered in a vaccine-like manner. IL-6 and IL-17 levels were significantly lower in the Ac-PLP-BPI-NH2-2-NP-treated mice compared to the mice group treated with blank colloidal gel, suggesting that the mechanism of suppression of EAE is due to a shift in the immune response away from Th17 production. The results of this study suggest that a one-time s.c. administration of Ac-PLP-BPI-NH2-2 formulated in a colloidal gel can produce long-term suppression of EAE by reducing Th17 proliferation.en_US
dc.publisherAmerican Chemistry Societyen_US
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in Molecular Pharmaceutics, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://doi.org/10.1021/mp200614q.en_US
dc.subjectAutoimmune diseaseen_US
dc.subjectImmune toleranceen_US
dc.subjectExperimental autoimmune encephalomyelitisen_US
dc.subjectColloidal gelen_US
dc.subjectPLGAen_US
dc.subjectChitosanen_US
dc.subjectAlginateen_US
dc.subjectBifunctional peptide inhibitoren_US
dc.titleVaccine-like Controlled-Release Delivery of an Immunomodulating Peptide to Treat Experimental Autoimmune Encephalomyelitisen_US
dc.typeArticleen_US
kusw.kuauthorBüyüktimkin, Barlas
kusw.kuauthorWang, Qun
kusw.kuauthorKiptoo, Paul
kusw.kuauthorStewart, John M.
kusw.kuauthorBerkland, Cory J.
kusw.kuauthorSiahaan, Teruna J.
kusw.kudepartmentPharmaceutical Chemistryen_US
dc.identifier.doi10.1021/mp200614qen_US
kusw.oaversionScholarly/refereed, author accepted manuscripten_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC3357633en_US
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record